In addition to its CNS focus, Jupiter is evaluating opportunities in longevity and metabolic health. Emerging data suggests that JOTROL’s inhibition of NLRP3, when combined with GLP-1 treatments, ...

NLRP3 inflammasome activation, pro-inflammatory cytokine production and pyroptosis are key features of inflammation that contribute to liver fibrosis progression, cirrhosis and end-stage liver failure ...

AZM-152 works by blocking the NLRP3 inflammasome, a crucial inflammatory pathway involved in BPD and other diseases. This compound specifically targets the receptor for hyaluronan-mediated ...

Nanjing Mingde New Drug Research Co. Ltd. has identified NLRP3 inflammasome inhibitors reported to be useful for the treatment of inflammation.

Jupiter Neurosciences (JUNS) announced a strategic focus on targeting the NLRP3 inflammasome in all upcoming clinical trials. This shift aims ...

With its ability to safely reach therapeutic levels in plasma and cross the blood-brain barrier, JOTROL represents a groundbreaking advance for targeting neuroinflammatory pathways like NLRP3.